All In Biotech

Drug Trial Radar · NCT04296370

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Fluzoparib±Apatinib Versus Physicians Choice Chemotherapy in the Treatment of HER2-negative Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations

Last checked: Nov 19, 2026Latest source record: Aug 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 474 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

474

Planned (sponsor's estimate)

Start

Jul 13, 2020

Primary completion

Jun 30, 2022

Study completion Jun 30, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Physicians Choice Chemotherapy, as treatment, in patients with a Germline BRCA Mutation and HER2-negative Metastatic Breast Cancer. The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 3 portion of the study.

Conditions

  • Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Interventions

  • Fluzoparib; ApatinibDrug

    Fluzoparib Orally twice daily; Apatinib Orally once daily

  • FluzoparibDrug

    Fluzoparib Orally twice daily

  • Physician's choice chemotherapyDrug

    Investigators will declare one of the following regimens: Capecitabine Vinorelbine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Safety Lead-in) dose limited toxicity (DLT)Time frame: up to 21 days
  2. (Safety Lead-in) Recommended Phase II Dose (RP2D)Time frame: up to 21 days
  3. (Phase 3) Progression free survival(PFS) in HER2-negative Metastatic Breast Cancer patientsTime frame: Radiological scans performed at baseline then every ~6 weeks up to 30 weeks, then every ~ 9 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu HengRui Medicine Co., Ltd.

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.